LexaGene Announces Change in Management and Appoints New Member to the Board of Directors
February 12 2021 - 7:56AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
develops fully automated rapid pathogen detection systems,
announces that Mr. Daryl Rebeck will resign from the Board and his
position as the President of the Company effective February 15,
2021, and Stephen J. Mastrocola has joined LexaGene’s Board of
Directors.
Dr. Jack Regan, LexaGene’s CEO and Founder, states, “I’m
immensely grateful to Daryl for being my partner and helping me
found this company four years ago. I would like to thank him for
all his hard work and leadership and wish him great success in his
future endeavors.”
Mr. Daryl Rebeck comments, “The pandemic has certainly presented
some challenges for me to travel to the Beverly office while based
outside of the country. I am confident that Jack and the current
management team will continue to move the company forward. I am
incredibly proud of what we’ve built at LexaGene, and the company
has my continued support.”
As a board member, Mr. Mastrocola brings almost 40 years of
accounting and auditing experience working with public and private
companies. Mr. Mastrocola recently retired from Ernst & Young
LLP (EY) after 19 years, where he was a senior assurance partner
and led EY’s New England Assurance Practice for several years.
Prior to EY, Mr. Mastrocola was an assurance partner at Arthur
Andersen LLP. Through his 40-year career at leading auditing firms,
he served primarily emerging and growth-oriented companies in the
life science sector with products in medical devices and
diagnostics. Mr. Mastrocola is a Certified Public
Accountant with extensive experience in various financial
transactions including IPOs, debt financings, mergers and
acquisitions, revenue recognition, internal controls and corporate
governance, including compliance matters. Mr. Mastrocola is also a
member of LaunchPad Venture Group and serves on the Boards of
Partners for Youth with Disabilities and the New England
Aquarium.
Dr. Regan continues, “We are extremely excited to have Steve
join our board. He brings strong leadership skills, a wealth of
knowledge, and connections in the industry that will be critical
for LexaGene to meet its growth goals in 2021 and beyond.”
To be added to the LexaGene email list, please subscribe on the
Company website.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately one
hour. The unique open-access feature is designed for custom testing
so that end-users can load their own real-time PCR assays onto the
instrument to target any genetic target of interest.
For further information, please contact:
Media ContactNicole RidgedaleDirector of
Corporate Marketing, LexaGene800.215.1824 ext
206nridgedale@lexagene.com
Investor RelationsJay AdelaarVice President of
Capital Markets, LexaGene800.215.1824 ext
207jadelaar@lexagene.com
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024